These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22934599)

  • 1. Analysis of human monoclonal antibodies generated by dengue virus-specific memory B cells.
    Friberg H; Jaiswal S; West K; O'Ketch M; Rothman AL; Mathew A
    Viral Immunol; 2012 Oct; 25(5):348-59. PubMed ID: 22934599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
    Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
    J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
    Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
    J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.
    de Alwis R; Beltramello M; Messer WB; Sukupolvi-Petty S; Wahala WM; Kraus A; Olivarez NP; Pham Q; Brien JD; Tsai WY; Wang WK; Halstead S; Kliks S; Diamond MS; Baric R; Lanzavecchia A; Sallusto F; de Silva AM
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1188. PubMed ID: 21713020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.
    Beltramello M; Williams KL; Simmons CP; Macagno A; Simonelli L; Quyen NT; Sukupolvi-Petty S; Navarro-Sanchez E; Young PR; de Silva AM; Rey FA; Varani L; Whitehead SS; Diamond MS; Harris E; Lanzavecchia A; Sallusto F
    Cell Host Microbe; 2010 Sep; 8(3):271-83. PubMed ID: 20833378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient.
    Schieffelin JS; Costin JM; Nicholson CO; Orgeron NM; Fontaine KA; Isern S; Michael SF; Robinson JE
    Virol J; 2010 Feb; 7():28. PubMed ID: 20132551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1).
    Gelanew T; Hunsperger E
    Virol J; 2018 Feb; 15(1):30. PubMed ID: 29409531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay.
    Hadjilaou A; Green AM; Coloma J; Harris E
    J Immunol; 2015 Oct; 195(7):3490-6. PubMed ID: 26320246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.
    Costin JM; Zaitseva E; Kahle KM; Nicholson CO; Rowe DK; Graham AS; Bazzone LE; Hogancamp G; Figueroa Sierra M; Fong RH; Yang ST; Lin L; Robinson JE; Doranz BJ; Chernomordik LV; Michael SF; Schieffelin JS; Isern S
    J Virol; 2013 Jan; 87(1):52-66. PubMed ID: 23077306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell responses during primary and secondary dengue virus infections in humans.
    Mathew A; West K; Kalayanarooj S; Gibbons RV; Srikiatkhachorn A; Green S; Libraty D; Jaiswal S; Rothman AL
    J Infect Dis; 2011 Nov; 204(10):1514-22. PubMed ID: 21930609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.
    Tsai WY; Lai CY; Wu YC; Lin HE; Edwards C; Jumnainsong A; Kliks S; Halstead S; Mongkolsapaya J; Screaton GR; Wang WK
    J Virol; 2013 Dec; 87(23):12562-75. PubMed ID: 24027331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection.
    Weiskopf D; Angelo MA; Sidney J; Peters B; Shresta S; Sette A
    J Virol; 2014 Oct; 88(19):11383-94. PubMed ID: 25056881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human antibody response to dengue virus infection.
    Wahala WM; Silva AM
    Viruses; 2011 Dec; 3(12):2374-95. PubMed ID: 22355444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
    Uno N; Ross TM
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotype-specific anti-Dengue virus NS1 mouse antibodies cross-react with prM and are potentially involved in virus production.
    Masrinoul P; Omokoko MD; Pambudi S; Ikuta K; Kurosu T
    Viral Immunol; 2013 Aug; 26(4):250-8. PubMed ID: 23941673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
    de Alwis R; Smith SA; Olivarez NP; Messer WB; Huynh JP; Wahala WM; White LJ; Diamond MS; Baric RS; Crowe JE; de Silva AM
    Proc Natl Acad Sci U S A; 2012 May; 109(19):7439-44. PubMed ID: 22499787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to Interrogating the Human Memory B-Cell and Memory-Derived Antibody Repertoire Following Dengue Virus Infection.
    Lyski ZL; Messer WB
    Front Immunol; 2019; 10():1276. PubMed ID: 31244836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes.
    Lecouturier V; Berry C; Saulnier A; Naville S; Manin C; Girerd-Chambaz Y; Crowe JE; Jackson N; Guy B
    Vaccine; 2019 Jul; 37(32):4601-4609. PubMed ID: 29706291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.